Cargando…

The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor–Treated Chronic Myelogenous Leukemia

Tyrosine kinase inhibitors (TKIs) have been linked to bone pain and linear growth attenuation in children with TKI-treated chronic myelogenous leukemia (CML). We describe the skeletal phenotype in an 11-year-old boy with chronic bone pain due to TKI-treated CML, including his response to intravenous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lavoie, Declan C T, Robinson, Marie-Eve, Johnston, Donna, Pagé, Marika, Konji, Victor N, Rauch, Frank, Ward, Leanne M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462212/ https://www.ncbi.nlm.nih.gov/pubmed/30997443 http://dx.doi.org/10.1210/js.2018-00268

Ejemplares similares

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Local Tumor Recurrence and Escape from Suppression of Bone Resorption With Denosumab Treatment in Two Adolescents With Giant Cell Tumors of Bone
por: Akel, Umar, et al.
Publicado: (2019)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective
por: Ghosh, K
Publicado: (2022)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience
por: Bommannan, KB, et al.
Publicado: (2022)

A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016)

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells
por: Mitrovský, Ondřej, et al.
Publicado: (2023)

Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients
por: Rivera, Donna R, et al.
Publicado: (2020)

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
por: Lei, Hu, et al.
Publicado: (2021)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
por: Ono, Takaaki
Publicado: (2021)

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
por: Okabe, Seiichi, et al.
Publicado: (2023)

Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
por: Okumura, Lucas M., et al.
Publicado: (2015)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

Myelomastocytic Blast Cell Crisis in Resistant Tyrosine Kinase Inhibitor Chronic Myelogenous Leukemia: Case Report and Review of Literature
por: Martinez-Cordero, Humberto, et al.
Publicado: (2019)

Extramedullary Involvement by Chronic Myelogeneous Leukemia in Five Patients With Unusual Clinicopathologic Features: A Review of the Effectiveness of Tyrosine Kinase Inhibitors
por: Soni, Abha, et al.
Publicado: (2016)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Intravenous Pamidronate for Refractory Lymphedema
por: Beigi, A A, et al.
Publicado: (2011)

ODP124 Sickle Cell Bone Disease and Response to Intravenous Bisphosphonates in Children
por: Todd Alexander, R, et al.
Publicado: (2022)

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
por: Chen, Z, et al.
Publicado: (2016)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

Acute Myelogenous Leukemia and Febrile Neutropenia
por: Herbers, Alexandra, et al.
Publicado: (2009)

The Neurological Safety of Epidural Pamidronate in Rats
por: Lee, Pyung Bok, et al.
Publicado: (2010)

Intravenous pamidronate for refractory rheumatoid arthritis
por: Salesi, Mansour, et al.
Publicado: (2012)

Pamidronate therapy for hypercalcemia of childhood malignancy
por: Sng, Andrew, et al.
Publicado: (2015)

Therapy with pamidronate in children with osteogenesis imperfecta
por: Marginean, Otilia, et al.
Publicado: (2017)

Applications of Microarray Technology to Acute Myelogenous Leukemia
por: Goswami, Rashmi S., et al.
Publicado: (2008)

Biomarkers for determining the prognosis in chronic myelogenous leukemia
por: Sweet, Kendra, et al.
Publicado: (2013)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
por: Janani, Gopalarethinam, et al.
Publicado: (2023)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

Genotype-phenotype correlations and long-term efficacy of pamidronate therapy in patients with osteogenesis imperfecta
por: Choi, Yunha, et al.
Publicado: (2022)

Four Cases of Chronic Myelogenous Leukemia in Mixed Phenotype Blast Phase at Initial Presentation Mimicking Mixed Phenotype Acute Leukemia with t(9;22)
por: Choi, Woojin, et al.
Publicado: (2014)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_74ieiuqjoeb3ia7u7jitt5r506